Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
In the quest for better medicines, attention is increasingly turning to cell-based therapies. Adoptive cell therapy has revolutionized clinical approaches to treat cancer. Aiming to fully support customers and advance the development of cell immunotherapy, Creative Biolabs provides a wide collection of services to predict and analyze the function of chimeric antigen receptor macrophage (CAR-MA), including CAR-MA cytokine release assay.
Macrophages are capable of killing target cells via phagocytosis and trogocytosis and MHC-II presentation of antigens taken up, as well as secretion of cytokine and effector molecules. Cytokines are mainly produced by macrophages and lymphocytes. When macrophages are exposed to inflammatory stimuli, they secrete cytokines such as tumor necrosis factor (TNF), IL-1, IL-6, IL-8, and IL-12. The binding of tumor antigen with the CAR receptor activates CAR-MA that mediates phagocytosis, activation of transcription factors such as NF-kB, and subsequent release of inflammatory cytokines, which in turn can activate T cell-mediated immunity against the tumor. In addition, CAR-MA could contribute to shifting the tumor microenvironment towards tumor rejection by releasing inflammatory cytokines. Therefore, cytokine release assays are fast and simple methods to evaluate the activation and anti-tumor efficacy of CAR-MA.
Fig.1 Closer insight into CAR-MA activation and anticancer mechanisms. (Abdin, 2021)
Most of the standardized techniques utilized for the measurement of immune cell cytokine release, such as enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunoSPOT (ELISPOT) assays), bioarray, or flow cytometry. Among them, the cytokine profiling array is a high-throughput ELISA-based antibody array for protein expression profiling of cytokines and related biomarkers. The ELISPOT assay captures the presence of cytokines immediately after secretion, in contrast to measurements that are skewed by receptor binding or protease degradation. The assay is one of the most sensitive cellular assays available.
Fig.2 Detection of cytokines (eg: IL-2) released by cells using ELISPOT technique. (Sachdeva, 2007)
Creative Biolabs offers multiple cytokines response assays that accelerate cell and gene therapy-based immuno-oncology drugs development and provide the analysis and assessment of the function of immune cells. Cytokine levels are measured using our optimized immunoassay technology for accurate quantification. We will work with you and your research team to determine the best method to present your test molecule. These assays are designed to be highly specific and reproducible with their broad usage in functional screening and functional characterization. Our team analyses your data to give you results that can be used in informing the next stages of your research. Please feel free to contact us for more information.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
